Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: Curr Metabolomics. 2013 Sep 1;1(3):239–250. doi: 10.2174/2213235x1130100005

Figure 4.

Figure 4

Observed change in the retention factor (k) for gliclazide (●), tolbutamide (▲) and acetohexamide (◆) on HPLC columns containing immobilized (a) normal HSA or (b) glycated HSA and in the presence of mobile phases containing various concentrations of myristic acid. All values shown in this figure are the averages of three replicates and had relative standard deviations in the range of ±0.1–1.6%.